NO961071L - Kjemiske forbindelser, deres fremstilling og anvendelse - Google Patents

Kjemiske forbindelser, deres fremstilling og anvendelse

Info

Publication number
NO961071L
NO961071L NO961071A NO961071A NO961071L NO 961071 L NO961071 L NO 961071L NO 961071 A NO961071 A NO 961071A NO 961071 A NO961071 A NO 961071A NO 961071 L NO961071 L NO 961071L
Authority
NO
Norway
Prior art keywords
alkyl
phenyl
alkoxy
phenoxy
substituted
Prior art date
Application number
NO961071A
Other languages
English (en)
Other versions
NO961071D0 (no
Inventor
Jesper Lau
Lars Jacob Stray Knutsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK104393A external-priority patent/DK104393D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO961071D0 publication Critical patent/NO961071D0/no
Publication of NO961071L publication Critical patent/NO961071L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Forbindelse med formel (I). eller et farmasøytisk akseptabelt salt. derav. hvor X er halogen, amino, perhalogen-metyl, cyan, C.-alkoksy,.-alkyltio eller C^-alkylamino; A er metyl, halo-genmetyl, cyanmetyl, aminometyl, vinyl, metyltiometyl eller metoksymetyl; Rer valgt fra gruppene bestående avhvor Q er nitrogen eller karbon, n er 1-3, og hvor gruppen (a) eventuelt kan være substituert med én eller to C-alkylgrupper, C.-alkenyl, C.-alkynyl, fenoksy, fenylsulfonyl, fenylsulfinyl, fenyltio, hydroksy, fenyl, q.-alkoksy eller C.-alkoksy-.-alkyl, fenl-tioalkyl eller. hvor Y er 0, S eller NZ, hvor Z er H, C.-alkyl eller fenyl, og hvor gruppen (b) eventuelt kan være substituert med C.-alkyl, C.-alkenyl, C_-alkynyl, fenoksy, fenyl, C^-alkoksy eller C.-alkoksy-C.-alkyl; ellerer -Reller -YR, hvor Y er oksygen eller svovel; RJ er C-alkyl,er fenyl eller C.-alkyl som kan være substituert med fenyl eller fenoksy, oger C.-alkyl eller C.-sykloalkyl som kan være substituert med fenyl eller fenoksy. Forbindelsene har blitt funnet anvendbare til behandling av sentral-nervesystemlidelser.
NO961071A 1993-09-17 1996-03-15 Kjemiske forbindelser, deres fremstilling og anvendelse NO961071L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK104393A DK104393D0 (da) 1993-09-17 1993-09-17 Kemiske forbindelser, deres fremstilling og anvendelse
DK31094 1994-03-16
PCT/DK1994/000344 WO1995007921A1 (en) 1993-09-17 1994-09-15 Chemical compounds, their preparation and use

Publications (2)

Publication Number Publication Date
NO961071D0 NO961071D0 (no) 1996-03-15
NO961071L true NO961071L (no) 1996-05-15

Family

ID=26063751

Family Applications (1)

Application Number Title Priority Date Filing Date
NO961071A NO961071L (no) 1993-09-17 1996-03-15 Kjemiske forbindelser, deres fremstilling og anvendelse

Country Status (10)

Country Link
US (1) US5589467A (no)
EP (1) EP0719275A1 (no)
JP (1) JPH11511436A (no)
AU (1) AU678053B2 (no)
CA (1) CA2171940A1 (no)
FI (1) FI961219A (no)
IL (1) IL110992A0 (no)
NO (1) NO961071L (no)
NZ (1) NZ273284A (no)
WO (1) WO1995007921A1 (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022497A (en) * 1996-03-13 1997-10-01 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
WO1997033591A1 (en) * 1996-03-13 1997-09-18 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
GB9610031D0 (en) * 1996-05-14 1996-07-17 Glaxo Group Ltd Chemical compounds
AU4377397A (en) * 1996-10-14 1998-05-11 Novo Nordisk A/S Novel therapeutically active adenosine derivatives
US6110902A (en) * 1997-06-23 2000-08-29 Moehler; Hanns Method for the inhibition of neuronal activity leading to a focal epileptic seizure by local delivery of adenosine
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723589D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
WO2001040799A2 (en) * 1999-12-03 2001-06-07 Cv Therapeutics, Inc. Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias
GB2372742A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
US7265111B2 (en) 2002-06-27 2007-09-04 Sanofi-Aventis Deutschland Gmbh Adenosine analogues and their use as pharmaceutical agents
ATE368048T1 (de) * 2002-08-15 2007-08-15 Cv Therapeutics Inc Partielle und volle agonisten von a1- adenosinrezeptoren
PT1758596E (pt) * 2004-05-26 2010-06-23 Inotek Pharmaceuticals Corp Derivados de purina como agonistas do receptor de adenosina a1 e processos para a sua utilização
RU2007114887A (ru) * 2004-09-20 2008-10-27 Инотек Фармасьютикалз Корпорейшн (Us) Производные пурина и способы их применения
CN101321460A (zh) * 2005-11-30 2008-12-10 伊诺泰克制药公司 嘌呤衍生物及其用法
CN101857622B (zh) * 2009-04-07 2014-12-03 中国医学科学院药物研究所 一种腺苷衍生物及其制备方法和应用
EP2523669B1 (en) 2010-01-11 2016-12-07 Inotek Pharmaceuticals Corporation Combination, kit and method of reducing intraocular pressure
AU2011230580A1 (en) 2010-03-26 2012-10-11 Inotek Pharmaceuticals Corporation Method of reducing intraocular pressure in humans using N6 -cyclopentyladenosine (CPA), CPA derivatives or prodrugs thereof
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
PL2807178T3 (pl) 2012-01-26 2017-12-29 Inotek Pharmaceuticals Corporation Bezwodne polimorfy azotanu (2R,3S,4R,5R)-5-(6-(cyklopentyloamino)-9H-puryn-9-ylo)-3,4-dihydroksytetrahydrofuran-2-ylo)metylu i sposoby ich wytwarzania
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
PH12015501492B1 (en) 2013-01-08 2015-09-28 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
MX2015013234A (es) 2013-03-15 2016-04-15 Inotek Pharmaceuticals Corp Formulaciones oftalmicas.
RU2712621C2 (ru) 2013-05-23 2020-01-30 Калвиста Фармасьютикалз Лимитед Азотсодержащие гетероциклические производные, полезные в качестве ингибитора калликреина плазмы
WO2015022546A1 (en) 2013-08-14 2015-02-19 Kalvista Pharmaceuticals Limited Inhibitors of plasma kallikrein
GB2517908A (en) 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
RS60600B1 (sr) 2016-05-31 2020-08-31 Kalvista Pharmaceuticals Ltd Derivati pirazola kao inhibitori kalikreina plazme
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
RU2020121151A (ru) 2017-11-29 2021-12-29 Калвиста Фармасьютикалз Лимитед Дозированные формы, содержащие ингибитор плазменного калликреина
GB201910116D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
GB201910125D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of angioedema
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
GB2591730A (en) 2019-12-09 2021-08-11 Kalvista Pharmaceuticals Ltd New polymorphs
GB201918994D0 (en) 2019-12-20 2020-02-05 Kalvista Pharmaceuticals Ltd Treatments of diabetic macular edema and impaired visual acuity
TW202228686A (zh) 2020-10-15 2022-08-01 英商卡爾維斯塔製藥有限公司 血管性水腫之治療
US20230381162A1 (en) 2020-10-23 2023-11-30 Kalvista Pharmaceuticals Limited Treatments of angioedema
US20240122909A1 (en) 2021-02-09 2024-04-18 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023002219A1 (en) 2021-07-23 2023-01-26 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023209381A1 (en) 2022-04-27 2023-11-02 Kalvista Pharmaceuticals Limited Formulations of a plasma kallikrein inhibitor

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB131501A (no) *
DE1545645A1 (de) * 1965-12-06 1969-08-21 Boehringer Mannheim Gmbh Verfahren zur Herstellung von disubstituierten Adenosin-Derivaten
JPS4935635B1 (no) * 1970-12-28 1974-09-25
US3910885A (en) * 1974-03-12 1975-10-07 Syntex Inc 4-Alkoxy nucleosides and intermediates therefore
DE3406533A1 (de) * 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
ATE50777T1 (de) * 1984-04-18 1990-03-15 Whitby Research Inc Cardio-vasodilatatore n-6-substituierte adenosine.
CA1254888A (en) * 1984-10-26 1989-05-30 Bharat Trivedi N.sup.6-bicycloadenosines
AU575438B2 (en) * 1984-10-26 1988-07-28 Warner-Lambert Company N6 - substituted deoxyribose analogues of adenosines
US4755594A (en) * 1986-01-31 1988-07-05 Warner-Lambert Company N6 -substituted adenosines
JPH0696534B2 (ja) * 1986-04-25 1994-11-30 ヘキストジヤパン株式会社 抗痴呆剤
AU8276187A (en) * 1986-10-31 1988-05-25 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
US4962194A (en) * 1987-04-02 1990-10-09 Warner-Lambert Company Method of preparing 51,N6-disubstituted adenosines from inosines
DE68916036T2 (de) * 1988-11-15 1994-09-29 Toa Eiyo Ltd Mittel zur behandlung und prophylaxe koronarer und zerebraler ischämischer erkrankungen.
US5017578A (en) * 1989-06-09 1991-05-21 Hoechst-Roussel Pharmaceuticals Inc. N-heteroaryl-purin-6-amines useful as analgesic and anticonvulsant agents
AU643235B2 (en) * 1989-09-15 1993-11-11 Gensia Pharmaceuticals, Inc. Methods of treating neurodegenerative conditions
EP0423777A3 (en) * 1989-10-19 1991-09-25 G.D. Searle & Co. Method of treating gastrointestinal motility disorders
IL99124A (en) * 1990-08-10 1998-02-22 Gensia Pharma Substituted imidazole analogs of aica riboside
US5308837A (en) * 1990-08-22 1994-05-03 Merrell Dow Pharmaceuticals Inc. 5'-amine substituted adenosine analogs as immunosuppressants
HUT61567A (en) * 1990-12-07 1993-01-28 Sandoz Ag Process for producing new pharmaceutical compositions comprising 2'-o-alkyladenosine derivatives and for producing 6-cyclohexyl-2'-o-methyladenosinehydrate
US5432164A (en) * 1991-10-24 1995-07-11 Novo Nordisk A/S C2,N6 -disubstituted adenosine derivatives
DK62592D0 (no) * 1992-05-14 1992-05-14 Novo Nordisk As
DK62692D0 (no) * 1992-05-14 1992-05-14 Novo Nordisk As
AU4772493A (en) * 1992-07-15 1994-02-14 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Sulfo-derivatives of adenosine
WO1994006438A1 (en) * 1992-09-11 1994-03-31 The Regents Of The University Of California Adenosine analogues and method of increasing adenosine release

Also Published As

Publication number Publication date
NZ273284A (en) 1997-03-24
JPH11511436A (ja) 1999-10-05
NO961071D0 (no) 1996-03-15
EP0719275A1 (en) 1996-07-03
AU7651994A (en) 1995-04-03
CA2171940A1 (en) 1995-03-23
IL110992A0 (en) 1994-11-28
WO1995007921A1 (en) 1995-03-23
FI961219A (fi) 1996-05-15
FI961219A0 (fi) 1996-03-15
US5589467A (en) 1996-12-31
AU678053B2 (en) 1997-05-15

Similar Documents

Publication Publication Date Title
NO961071L (no) Kjemiske forbindelser, deres fremstilling og anvendelse
NO912132L (no) Arylpyrroler, fremgangsmaate for deres fremstilling og anvendelse som pestiside forbindelser.
BR9914696A (pt) Composto, processo para tratamento de distúrbio mediado por ciclo-oxigenase-2 em um indivìduo, e, composição farmacêutica
DE69903988T2 (de) Fungizide Trifluorophenyltriazolopyrimidine
DK118286A (da) Terapeutisk aktive nucleosider, deres anvendelse og farmaceutiske kompositioner indeholdende forbindelserne
DE69318077T2 (de) Triazolylthiomethylthiocephalosporin-Hydrochlorid, sein kristallines Hydrat und seine Herstellung
KR890011902A (ko) 디데옥시디데히드로카르보시클릭 뉴클레오시드
IT1205958B (it) Derivati di acido chinolincarbossilico e procedimento per la loro preparazione
DK0518558T3 (da) 1-methylcarbapenemderivater, deres fremstilling og deres anvendelse som antibiotika
PT91081A (pt) Processo para a preparacao de derivados piperidina 1,3-dissubstituida
ES8700673A1 (es) Un procedimiento para preparar derivados de acido griseolico
DK0626367T3 (da) (7S)-7- (2R)-2-(3-chlorphenyl)-2-hydroxyethylamino -5,6,7,8-tetrahydronapthalen-2-yloxyeddikesyre og farmaceutisk acceptable salte deraf med beta3-adrenerg agonistvirkning, farmaceutiske præparater og laboratoriereagenser som indeholder den.
NO20012965L (no) Sulfonyloksazolaminer som terapeutisk aktive forbindelser
EP0217747A3 (en) Nematocidal agents
DK0431579T3 (da) Substituerede cyclohexener som midler med virkning på centralnervesystemet
DK0554794T3 (da) Aminobenzoesyrederivater
DE68903907D1 (de) Cyclisches peptid, seine herstellung und seine verwendung zur behandlung von cardiovasculaeren stoerungen.
DK49487A (da) 9-n-substituerede derivater af erythromycylamin til anvendelse imod infektioner med gram-positive bakterier
ES523426A0 (es) Un metodo para preparar nuevos derivados de guanina
DK96086A (da) 8-thiotetrahydroquinolinderivater, deres fremstilling og anvendelse som laegemidler
DK475487D0 (da) Mono- og diacylderivater af ll-f28249-forbindelser samt deres anvendelse
NO940122L (no) Nye adenosinderivater
ES2166937T3 (es) Metodo para preparar n2-arilsulfonil-l-argininamidas.
NO171502C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive thiadiazolylacetamidcefem-derivater
NO951812L (no) Pyrrolderivater, deres fremstilling og anvendelse